Perceptive Advisors LLC Reduces Stock Holdings in Artivion, Inc. $AORT

Perceptive Advisors LLC reduced its holdings in shares of Artivion, Inc. (NYSE:AORT) by 4.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,637,290 shares of the company’s stock after selling 85,000 shares during the period. Artivion makes up 1.2% of Perceptive Advisors LLC’s holdings, making the stock its 23rd largest position. Perceptive Advisors LLC’s holdings in Artivion were worth $59,958,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Glenmede Trust Co. NA acquired a new stake in Artivion in the first quarter worth about $295,000. Bank of America Corp DE increased its holdings in shares of Artivion by 0.8% during the first quarter. Bank of America Corp DE now owns 522,515 shares of the company’s stock valued at $19,135,000 after acquiring an additional 3,980 shares in the last quarter. Amundi raised its position in shares of Artivion by 7.5% in the 1st quarter. Amundi now owns 7,186 shares of the company’s stock valued at $263,000 after purchasing an additional 501 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Artivion by 33.4% in the 1st quarter. California State Teachers Retirement System now owns 51,213 shares of the company’s stock valued at $1,875,000 after purchasing an additional 12,825 shares during the last quarter. Finally, Royal Bank of Canada boosted its stake in Artivion by 73.1% in the 1st quarter. Royal Bank of Canada now owns 93,676 shares of the company’s stock worth $3,430,000 after purchasing an additional 39,553 shares in the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AORT has been the topic of several research analyst reports. Needham & Company LLC reissued a “buy” rating and set a $44.00 target price on shares of Artivion in a research report on Monday, July 20th. Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a research note on Monday, June 1st. Citigroup reissued a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Citizens Jmp cut their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research report on Friday, May 8th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $36.00 target price on shares of Artivion in a research report on Tuesday, June 16th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.17.

Insider Activity

In related news, SVP Andrew M. Green sold 44,001 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the transaction, the senior vice president owned 60,259 shares of the company’s stock, valued at $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is currently owned by company insiders.

Artivion Stock Performance

Shares of NYSE AORT opened at $26.82 on Friday. The company has a 50 day simple moving average of $23.10 and a two-hundred day simple moving average of $31.70. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of 111.75 and a beta of 1.26. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. Artivion, Inc. has a 12 month low of $19.16 and a 12 month high of $48.25.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.